Viewray, Inc

Description

21-Jan-2008 ViewRay Incorporated, a medical device manufacturer, announced today the close of a $25 million Series B financing. Founded in 2004, ViewRay Incorporated is focused on the development of a real-time magnetic resonance imaging (MRI) guided radiation therapy device for the treatment of cancer patients. The financing was led by OrbiMed Advisors and Fidelity Biosciences, and was joined by Aisling Capital, and Kearny Venture Partners. "This substantial funding from blue-chip biomedical investors is a first in our industry and a testament to the promise of ViewRay’s technology to help cancer patients. More importantly, it allows us to accelerate the development of our system, the first device to promise real-time volumetric imaging simultaneous with radiation treatment," explained ViewRay CEO William Wells. The ViewRay Renaissance™ System 1000 technology was invented by James F. Dempsey, Ph.D., associate professor in the Department of Radiation Oncology at the University of Florida and has been exclusively licensed by the Company from the University of Florida.

OrbiMed is the world's largest healthcare-dedicated investment firm, with over $6 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

May 30, 2013 Prabhakar Tripuraneni, MD, chief medical officer at ViewRay™ Incorporated and head of radiation oncology at Scripps Green Hospital in La Jolla, California, has been selected to receive a Gold Medal from the American Society for Radiation Oncology (ASTRO). The Gold Medal is ASTRO's highest honor, bestowed on highly regarded members who have made outstanding contributions to the field of radiation oncology. The award will be presented at ASTRO's 2013 Annual Meeting in September. “Over the course of a long and distinguished career, Dr. Tripuraneni has made unique contributions as both a clinical scientist and tireless voluntary leader in the field of radiation oncology," said past ASTRO Gold Medalist Christopher Rose, MD, FASTRO, chief technical officer for Valley Radiotherapy Associates Medical Group and Vantage Oncology, Inc., and a member of ViewRay’s Scientific Advisory Board. “With his tremendous energy, dedication and passion for excellence, Dr.

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy. For more information, visit http://www.viewray.com. ViewRay is a trademark of ViewRay Incorporated. ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. To learn more, visit http://www.astro.org. ViewRay is a trademark of ViewRay Incorporated. ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

Products & services

Similar companies nearby